What is the optimal strategy for postoperative treatment with aromatase inhibitors in the adjuvant setting?
Author(s): Janicke F, Pronzato P Affiliation(s): Center of Gynecology, Obstetrics and Pediatrics, University Hospital Hamburg-Eppendorf, Martinistr 52, Hamburg D-20246, Germany. Publication date & source: 2006-12, Best Pract Res Clin Endocrinol Metab., 20 Suppl 1:S31-45. Publication type: After several decades as the gold standard endocrine adjuvant therapy for hormone-receptor-positive (HR+) early breast cancer, tamoxifen is now being displaced by the third-generation aromatase inhibitors (AI). In large, randomized, controlled trials the AIs have demonstrated superior efficacy and at-least equivalent tolerability to tamoxifen, findings which are reflected in international guidelines, which now recommend the inclusion of an AI in adjuvant therapy for HR+ disease in postmenopausal women. To date, two treatment strategies have been investigated and were shown to significantly improve outcomes compared with 5 years of tamoxifen. Upfront substitution of tamoxifen with letrozole or anastroz
